Higher TyG index linked to increased renal function progression risk in patients with CKD stages 3–4
This multicenter retrospective cohort study included 53,607 patients with CKD stages 3–4. The primary exposure was the baseline TyG index, compared across quartiles with the second quartile (Q2) as the reference. The median follow-up duration was 31.18 months. The primary outcome was renal function progression, which occurred in 19,619 (36.6%) patients.
Regarding the main results, each 1-unit increase in the continuous TyG index was associated with a 10% higher risk of renal function progression (Hazard Ratio 1.10; 95% CI 1.07–1.12). When analyzed by quartiles, the highest quartile (Q4) demonstrated a significantly increased risk compared to Q2 (Hazard Ratio 1.17; 95% CI 1.12–1.22). Additionally, the association between the TyG index and renal function progression was non-linear and U-shaped, with the lowest risk (nadir) observed at a TyG index of approximately 8.6–8.8.
Safety and tolerability data were not reported, as were specific adverse events or discontinuations. The study noted that results were robust in sensitivity analyses, including a competing-risk model. However, because this was a retrospective cohort study, the TyG index is described as an independent predictor rather than a causal agent. No funding conflicts were reported.
The TyG index may serve as a valuable tool for early risk stratification in patients with CKD stages 3–4. Clinicians should interpret these associations cautiously, recognizing the limitations inherent to observational research.